Results 231 to 240 of about 65,601,074 (263)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Bridging assessment, biomarkers, and interventions: progress in muscle health research. [PDF]

open access: yesFront Rehabil Sci
Oranchuk DJ   +3 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

The Dutch Nationwide Pathology Databank and its central role in health research. [PDF]

open access: yesJ Pathol Inform
Siebers AG   +9 more
europepmc   +1 more source

MyBioScope: a new frontier in gut microbiome and health research. [PDF]

open access: yesBioresour Bioprocess
Žukauskaitė K   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy